[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uremia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uremia":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,68,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100607529","dynamic-breath-voc-profiling-as-a-non-invasive-tool-to-assess-hemodialysis-adequacy-100607529",false,"NCT07189741","Dynamic Breath VOC Profiling as a Non-invasive Tool to Assess Hemodialysis Adequacy","1: Age:18-85\n\n2: Maintenance hemodialysis (HD) group: diagnosed with chronic kidney disease stage 5 (uremia), receiving regular HD for ≥3 months.\n\n3: Healthy control group: with no history of major acute or chronic diseases.\n\n4: Capable of understanding the research procedures and voluntarily providing written informed consent.\n\n1. Active infection\n2. History or current diagnosis of malignancy\n3. Severe hepatic insufficiency\n4. Unable to comply with breath testing or blood sampling; or refusal or inability to provide informed consent.\n5. Deemed ineligible for participation based on the investigator's judgment.",true,"ALL","18 Years","85 Years",{"count":20,"type":21},50,"ESTIMATED","OBSERVATIONAL","What is this study about? This is an observational study. The goal is to find out whether tiny chemicals in breath, called volatile organic compounds (VOCs), can help show if a hemodialysis session works well enough (\"dialysis adequacy\"). Hemodialysis is a treatment that uses a machine to remove waste and extra fluid from the blood.\n\nMain questions Which breath chemicals change in people receiving hemodialysis when we compare samples collected before dialysis with samples collected after the same dialysis session? Do these changes help indicate whether a dialysis session is adequate (that is, whether it worked as intended)? How do the breath chemicals of people receiving hemodialysis differ from those of healthy adults? During the dialysis session, which blood test results go up or down? Which ones are most different from the usual healthy range? Who can take part Adults aged 18-85 years. Hemodialysis group: people with chronic kidney disease stage 5 who receive maintenance hemodialysis for at least three months.\n\nHealthy comparison group: adults without major acute or chronic illnesses. Final eligibility will follow the approved study protocol and screening. What will happen if you join Hemodialysis group Provide one breath sample before a routine dialysis session and one breath sample after the same session.\n\nHave a small blood draw at those same time points. Your usual medical care will not change because of this study. Healthy comparison group Provide one breath sample and one small blood draw at a single visit. Time and visits For people receiving hemodialysis: both breath and blood samples are collected around one dialysis session (before and after).\n\nFor healthy adults: all procedures are finished in one scheduled visit. The study plans to include about 22 people on hemodialysis and about 23 healthy adults. These numbers may change slightly as enrollment proceeds.\n\nHow your samples are used Breath samples will be analyzed with gas chromatography-mass spectrometry (GC-MS), a laboratory method that separates and identifies very small amounts of chemicals in breath.\n\nBlood samples will be tested for routine biochemistry and immune measures to see which results change during dialysis and which results are different from the healthy range.\n\nThe study does not test a new drug or device and does not change your treatment.\n\nPossible benefits You may not receive a direct benefit. The knowledge from this study may help doctors find simple, non-invasive ways to judge whether dialysis works well, which could improve care for people with kidney failure in the future.\n\nPossible risks or discomforts Breath collection is non-invasive and usually causes no discomfort. Blood draws may cause brief pain, a small bruise, or lightheadedness in some people.\n\nPrivacy and data protection We label samples and data with codes instead of names. Only authorized staff can link the codes to your identity.\n\nStudy results may be published in journals or at meetings, but no information that can identify you will be shared.\n\nWhere and when Location: Shanghai Second People's Hospital (Department of Nephrology, Dialysis Unit).\n\nStudy period: September 1, 2025 to June 30, 2027. Sampling is expected during routine care for people on dialysis and during one visit for healthy adults.\n\nStudy team Principal Investigator: Tao Xiaoyang, Shanghai Second People's Hospital.",[25,26,27],"Uremia","Uremia; Chronic","Hemodialysis","NOT_YET_RECRUITING","2025-09-22",{"date":31,"type":32},"2025-09-24","ACTUAL",{"date":34,"type":21},"2025-09-30",{"date":36,"type":21},"2027-06-30",{"name":38,"class":39},"Second People's Hospital, Shanghai","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":40},"100334101","timing-of-renal-replacement-therapy-in-the-critically-ill-patients-100334101","NCT03629977","Timing of Renal Replacement Therapy in the Critically Ill Patients","Early vs Late CRRT, a Propensity Matched Multicenter Cohort Study","TORRT","Inclusion Criteria:\n\n\\*Critically ill patients admitted to intensive care units in Stockholm at: Karolinska University Hospital (Solna and Huddinge) and at Södersjukhuset.\n\n\\*Patients over 18 years of age\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years\n* Patients with DNAR (do not attempt resuscitation)-orders\n* Patients dying within 12 hours of commencing renal replacement therapy.",{"count":50,"type":21},50000,"1 Year","Background: Severe acute kidney injury (AKI) among critically ill patients is sometimes treated with renal replacement therapy (RRT), and in Sweden continuous RRT (CRRT) is the dominant modality used in this population.\n\n* The optimal timing of renal replacement therapy (RRT) initiation in critically ill patients with acute kidney injury (AKI) is unknown\n* No consensus to guide clinical practice on this issue\n* Lack of consistency regarding outcome measurements; should we look at morbidity or mortality?\n* Wide variability in the timing of RRT initiation in the intensive care unit (ICU) population\n\nHypothesis: This is an important knowledge gap in the support of critically ill patients with AKI and we hypothesize that early initiation of RRT is beneficial.\n\nMethods: The present study aims to test this hypothesis by using a large scale high resolution intensive care database, the Clinisoft repository. In this database, we have information on \\>60 000 patients from three different hospitals and five ICUs, during the years 2005 up until today. The repository will be crossmatched, using the unique Swedish national ID number, with hospital records; to gather information on preexisting illnesses, chronic medication and post-ICU outcomes. It is likely that over 5%, more than 3000 patients, have been treated with RRT. We will categorize these patients into \"early\" and \"late\" groups using both biomarker data and clinical data. Importantly, early and late RRT can be categorized using biomarkers, like urea and creatinine; using degree of fluid accumulation, by level of pH in blood and just by using hours-days after ICU admission. All possible definitions of early\u002Flate RRT initiation can be tested in this study.\n\nOutcomes: Our primary outcome is 90 day mortality. Secondary outcomes include: mortality at 30, 60, 180 and 365 days. Two- and three year mortality.\n\nMorbidity, measured as end-stage renal disease (ESRD) for 90-day survivors. ICU length of stay, hospital length of stay.",[54,25,55,56,57],"Acute Kidney Injury","Fluid Overload","Dialysis; Complications","Critical Illness","RECRUITING","2025-08-26",{"date":61,"type":32},"2025-09-03",{"date":63,"type":21},"2025-11-01",{"date":65,"type":21},"2027-04-01",{"name":67,"class":39},"Karolinska University Hospital",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100592845","phase-4-bcd-to-measure-the-ed95-of-remimazolam-assisted-sedation-in-arteriovenous-fistula-creation-surgery-100592845","NCT06998732","BCD to Measure the ED95 of Remimazolam-Assisted Sedation in Arteriovenous Fistula Creation Surgery","Using Biased Coin Design (BCD) to Measure the ED95 of Remimazolam-Assisted Sedation in Arteriovenous Fistula Creation Surgery","BCD","Inclusion Criteria:\n\n* 18-65 years old (including borderline values).\n* Elective surgical patients under local anaesthesia for operation of AVF\n* Voluntary participation in this study and signing of informed consent.\n* American Society of Anesthesiologists (ASA) classification \\\u003C Grade IV.\n* BMI range: 18-28kg\u002Fm2 (including borderline values).\n\nExclusion Criteria:\n\n* hypersensitivity to remimazolam or benzodiazepines.\n* patients with severe cardiac, pulmonary, neurological diseases or liver failure. -- Preoperative use of sedative drugs, anticonvulsants, etc.\n* patients who cannot cooperate with postoperative recovery or follow-up.\n* vulnerable groups, including those with mental illness, cognitive impairment, critically ill patients, pregnant women, illiterates, etc.","65 Years",{"count":78,"type":21},40,"INTERVENTIONAL",[81],"PHASE4","This study intends to measure the ED95 of remimazolam-assisted sedation in arteriovenous fistula creation by BCD.",[25],[85,86,87,88],"Biased Coin Design","uremia","remimazolam","ED95","2025-05-22",{"date":91,"type":32},"2025-05-31",{"date":93,"type":21},"2025-06-01",{"date":95,"type":21},"2025-10-31",{"name":97,"class":39},"Gang Chen",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":79,"phases":107,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":40},"100534054","multi-center-clinical-study-on-hemoperfusion-of-kha80-100534054","NCT06233838","Multi-center Clinical Study on Hemoperfusion of KHA80","Prospective, Multicenter, Randomized, Open Label Study on the Efficacy and Safety of Comparison of KHA80 Blood Perfusion Combined With Hemodialysis and Conventional Hemodialysis in Clearing IL-6, β2-MG and PTH in Maintenance Hemodialysis Patients","Inclusion Criteria:\n\n1. Age ≥18 years old, regardless of sex;\n2. According to the 2012 KDIGO guidelines, it was diagnosed as CKD5 (EGFR ≦ 15ml\u002F(min ˙ 1.73m2));\n3. receive regular hemodialysis (including hemodialysis filtration) for 4 hours twice a week for ≧3 months;\n4. blood β 2-mg ≥ 30 mg\u002FL and\u002For PTH ≥ 600 pg\u002FmL and\u002For IL-6 ≥ 16.2 pg\u002FmL;\n5. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. Those who are known to have allergic reactions, contraindications or intolerance to the materials of dialyzers and hemoperfutors;\n2. Patients with severe bleeding tendency and active bleeding, or with definite coagulation dysfunction, with a platelet count of \\\u003C 60× 109\u002FL;\n3. Hemodialysis blood flow \\\u003C 200 ml\u002Fmin.\n4. Kt\u002FV\\\u003C1.2；\n5. Serum albumin \\\u003C 30g\u002FL;\n6. Parathyroid resection within one year;\n7. people with low blood pressure and severe cardiopulmonary insufficiency;\n8. lactating or pregnant women or those who plan to be pregnant within one year;\n9. infection, history of malignant tumor, active stage of rheumatic immune disease;\n10. Patients whose life expectancy is less than one year;\n11. Other clinical researchers are currently or recently (within 30 days);\n12. According to the researcher's judgment, the patient has other unsuitable conditions.",{"count":106,"type":21},394,[108],"NA","To evaluate the decreasing rate of blood IL-6, β2-MG and PTH in maintenance hemodialysis patients in the 52nd week compared with routine hemodialysis.",[25,111,112],"Uremic Osteodystrophy","Dialysis Related Complication",[114,115,116,117,118],"KHA80","Maintenance hemodialysis","IL-6","β2-MG","PTH","2025-01-10",{"date":121,"type":32},"2025-01-14",{"date":123,"type":21},"2025-01-13",{"date":125,"type":21},"2027-05-31",{"name":127,"class":39},"First Affiliated Hospital of Fujian Medical University"]